You just read:

BerGenBio: Updated PhII Clinical Data With Selective AXL Inhibitor Bemcentinib Strengthens its Potential to Improve NSCLC Patient Outcomes

News provided by

BerGenBio ASA

25 Sep, 2018, 15:18 BST